| Pfizer AG - Caverject 20 ug, Injektionspräparat |
| 52510 | | 03 | | Caverject 20 ug | | Injektionspräparat | | G04BE01 | | Alprostadil | | 30.04.2013 | | |
|
| Composition |
| Praeparatio cryodesiccata: alprostadilum 20 µg, lactosum monohydricum, alfadexum, natrii citras dihydricus, acidum hydrochloridum aut natrii hydroxidum, pro vitro.
Solvens: conserv.: alcohol benzylicus 8.4 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. |
| Packungsbestandteile |
| Praeparatio cryodesiccata: | | Préparation injectable | | | | | | Principe actif | Concentr. |
|---|
| Alprostadil | 20 µg |
| | | | Agents auxilliaires |
|---|
| Acidum Hydrochloridum aut Natrii Hydroxidum | | Alfadexum | | Lactose Monohydrate | | Natrii Citras Dihydricus |
|
| Solvens | | Préparation injectable | | | | | | | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Alcohol Benzylicus | 8.4 mg/ml | conserv. |
|
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 105 | Flacon perforable | DDP | DDP | A | | Oui |
|
